Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,211.8
-2.3 (-0.07%)

 

  • STI Straits Times Index
    3,211.8
    -2.3 (-0.07%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,569.8
    -1.4 (-0.09%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,578.1
    -109.7 (-0.40%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,984.4
    16.7 (0.56%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,952.3
    -70.8 (-0.29%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,221.7
    24.4 (0.39%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,168.2
    -2.1 (-0.10%)
    Index delayed 20 minutes
  • XAO XAO
    6,952.3
    107.7 (1.57%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 511.6M
  • Value: 507.5M
  • Rise: 144
  • Fall: 132
  • Unch: 550

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.185-0.001
SunMoonFood^0.049+0.009
TEE Intl0.058+0.003
YZJ Shipbldg SGD1.090-0.040
Golden Agri-Res0.215-0.005
Interra Resource^0.066+0.005
Tritech0.025+0.001
AusGroup^0.032-0.001
JCG Investment0.002-
Y Ventures0.111+0.004

World Indices

World Indices
Name Last Change
Nasdaq 8,734.9 +17.6
HSI 27,557.9 -129.9
HSCEI 10,804.4 -33.7
Jakarta 6,222.9 +25.6
Nikkei 225 23,952.3 -70.8
SSE Comp 2,984.4 +16.7
Shanghai A 3,127.2 +17.5
Shanghai B 247.1 +1.2
PSE Comp 0.0
KOSPI 2,168.2 -2.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 16 Dec 2019 15:46
Last (SGD): 0.210 Change: -0.005 High: 0.215 Remarks: -
Change (%): -2.33 Low: 0.210
Open 0.215 Yesterday's Close 0.215
Buy Price 0.210 Sell Price 0.215
Buy Volume ('000) 12.7 Sell Volume ('000) 363.2
Cumulative Volume ('000) 110.6 Cumulative Value 23,279
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.01801 Trailing EPS (SGD) e 0.01890 NAV (SGD) b 0.1412
PE a 11.660 Trailing PE f 11.109 Price / NAV b 1.4873
Dividend (SGD) d 0.005492 Cash In Hand (SGD) g 0.0781 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 2.615 Price / Cash In Hand g 2.689 Treasury Shares h -
Beta - 75 Daysi 0.020 R-Squared - 75 Days(%)i 0.01 Market Cap (M) 63.090
Beta - 500 Daysi 0.284 R-Squared - 500 Days (%)i 0.82 Enterprise Value (M) 43.512
Piotroski F Score - Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 32.9928 6-Month VWAP 0.207 Free Float (%) 20.1
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 22 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 63.090 11.660 11.109 1.4873 2.615
Industry Medical & Biotechnology SGX 992.265 22.599 23.385 1.3831 1.878
Pharmaceuticals: Major SGX 63.090 11.662 11.109 1.4869 2.615
Global Peer JOHNSON & JOHNSON NYSE 372,093.781 24.325 26.295 6.3923 2.533
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 235,021.066 18.594 19.895 4.4745 1.812
Global Peer MERCK & CO INC NYSE 227,075.956 36.507 24.383 8.4610 2.272
Global Peer PFIZER INC NYSE 212,122.820 19.021 13.082 3.2592 3.719
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 149,605.568 30.408 26.307 8.4772 1.748
Global Peer ABBVIE INC NYSE 129,899.549 22.963 40.229 -15.7915 4.497
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 126,888.419 58.981 61.861 10.4314 2.736
Global Peer SANOFI SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 124,793.656 24.492 30.340 1.9446 2.307
Global Peer ELI LILLY AND COMPANY NYSE 116,684.720 36.103 27.344 34.4962 2.038
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 114,704.467 23.744 19.790 7.9070 4.425
Other Global Peers NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), ALLAKOS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CHINARES PHARMA (HKEx), INNOVENT BIO-B (HKEx), CMS (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HENLIUS-B (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), JUNSHI BIO-B (HKEx), SSY GROUP (HKEx), RA PHARMACEUTICALS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), CHINAGRANDPHARM (HKEx), AKCEA THERAPEUTICS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), ZYMEWORKS INC (NYSE), PRINCIPIA BIOPHARMA INC (NASDAQ), FORTY SEVEN INC (NASDAQ), CANSINOBIO-B (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), CSTONE PHARMA-B (HKEx), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ATHENEX INC (NASDAQ), UNITED LAB (HKEx), PHIBRO ANIMAL HEALTH CORP (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), PETIQ INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), QUANTERIX CORPORATION (NASDAQ), HUA MEDICINE-B (HKEx), AKERO THERAPEUTICS INC (NASDAQ), IGBB (Bursa), AC IMMUNE SA (NASDAQ), PROVENTION BIO INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), AKORN INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), 89BIO INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), EVOLUS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), LANNETT CO INC (NYSE), TOT BIOPHARM-B (HKEx), GRITSTONE ONCOLOGY INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), BIOMX INC (NYSE American), AFT PHARMACEUTICALS LTD (ASX), HOOKIPA PHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), NC HEALTHCARE (HKEx), LOGICBIO THERAPEUTICS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), VERU INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), OBSEVA SA (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), CHARMACY PHAR (HKEx), SCPHARMACEUTICALS INC (NASDAQ), Merck Tbk. (IDX), PHASEBIO PHARMACEUTICALS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), PALLA PHARMA LTD (ASX), IMMUNIC INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), THE FS ALSEC ALPHASECTOR (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), Phapros Tbk. (IDX), TREVI THERAPEUTICS INC (NASDAQ), NOVAN INC (NASDAQ), BAUDAX BIO INC (NASDAQ), EYENOVIA INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ALLENA PHARMACEUTICALS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), NEP INTERLONG (HKEx), IP (SET), MEDLAB CLINICAL LIMITED (ASX), MOLECULIN BIOTECH INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), BIOHLDG (Bursa), NOVA (Bursa), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), ZOMEDICA PHARMACEUTICALS CORP (NYSE American), EDESA BIOTECH INC (NASDAQ), ENTERA BIO LTD (NASDAQ), TELIGENT INC NEW (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), NOXOPHARM LTD (ASX), AERPIO PHARMACEUTICALS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), SINOLIFE UTD (HKEx), EXOPHARM LTD (ASX), CITIUS PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), CRESO PHARMA LTD (ASX), AILERON THERAPEUTICS INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), RACE ONCOLOGY LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), FARMAFORCE LTD (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), NOVUS THERAPEUTICS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), GENPREX INC (NASDAQ), FIJI KAVA LTD (ASX), GEMPHIRE THERAPEUTICS INC (NASDAQ), SIENNA BIOPHARMACEUTICALS INC (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.010
-4.55 %
10 Days --0.015
-6.67 %
20 Days -+0.010
+5.00 %
Medium Term Return 3 Months -+0.012
+6.06 %
6 Months -+0.014
+7.14 %
1 Year 0.006+0.015
+10.77 %
Annualised Return Annualised --
+10.77 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.160 - 0.240 Change From 1 Year Low +0.050 % Change From 1 Year Low (%) +31.25
Change From 1 Year High -0.030 % Change From 1 Year High (%) -12.50
2 Years Range 0.160 - 0.305 Change From 2 Years Low +0.050 % Change From 2 Years Low (%) +31.25
Change From 2 Years High -0.095 % Change From 2 Years High (%) -31.15
5 Years Range 0.160 - 0.305 Change From 5 Years Low +0.050 % Change From 5 Years Low (%) +31.25
Change From 5 Years High -0.095 % Change From 5 Years High (%) -31.15
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) -19.23 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
13 Dec 2019 0.215 0.215 0.215 0.215 - -
12 Dec 2019 0.215 0.215 0.215 0.215 - -
11 Dec 2019 0.215 0.215 0.215 0.215 60,000 0.2150
10 Dec 2019 0.215 0.215 0.215 0.215 282,000 0.2150
09 Dec 2019 0.220 0.220 0.215 0.215 30,200 0.2200
06 Dec 2019 0.220 0.225 0.220 0.220 94,900 0.2237
05 Dec 2019 0.220 0.220 0.215 0.215 11,100 0.2152
04 Dec 2019 0.215 0.215 0.215 0.215 50,000 0.2150
03 Dec 2019 0.215 0.215 0.215 0.215 10,500 0.2150
02 Dec 2019 0.220 0.220 0.220 0.220 130,000 0.2200
29 Nov 2019 0.220 0.225 0.215 0.225 33,700 0.2180
28 Nov 2019 0.215 0.220 0.215 0.220 165,000 0.2179
27 Nov 2019 0.220 0.225 0.215 0.215 381,100 0.2206
26 Nov 2019 0.215 0.215 0.210 0.215 140,500 0.2150
25 Nov 2019 0.210 0.215 0.210 0.210 82,100 0.2100
22 Nov 2019 0.205 0.215 0.205 0.210 2,325,300 0.2100
21 Nov 2019 0.205 0.210 0.205 0.210 3,082,100 0.2051
20 Nov 2019 0.205 0.210 0.205 0.210 59,700 0.2071
19 Nov 2019 0.210 0.210 0.200 0.210 262,400 0.2074
18 Nov 2019 0.205 0.220 0.205 0.210 713,800 0.2105
15 Nov 2019 0.199 0.210 0.199 0.200 633,100 0.2040
14 Nov 2019 0.200 0.200 0.199 0.199 40,000 0.1999
Summary
Current 2 Weeks
(02 Dec 2019 to 13 Dec 2019)
0.220 0.225 0.215 0.215 668,700 -
Previous 2 Weeks
(18 Nov 2019 to 29 Nov 2019)
0.205 0.225 0.205 0.225 7,245,700 -
4 Weeks from
(18 Oct 2019 to 15 Nov 2019)
0.198 0.225 0.198 0.200 2,397,600 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.